AVEO · Aveo Pharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $30.45M | $25.30M | $20.92M | - | $20.00M | $7.56M | $1.92M | - | $3.60M | $749.0K |
| Cost of Revenue | $3.96M | $3.06M | $2.43M | - | - | - | - | - | - | - |
| Gross Profit | $26.48M | $22.24M | $18.49M | - | - | - | - | - | - | - |
| R&D | $11.07M | $12.32M | $10.16M | - | $7.50M | $6.88M | $5.80M | - | $5.86M | $4.42M |
| SG&A | $17.58M | $17.07M | $17.34M | - | $15.14M | $14.92M | $3.67M | - | $5.80M | $3.74M |
| Total Operating Expenses | $32.62M | $32.46M | $29.93M | - | $24.39M | $22.62M | $21.04M | - | $11.66M | $8.16M |
| D&A | - | - | $17.0K | - | - | - | $17.0K | - | - | - |
| Operating Income | ($2.17M) | ($7.15M) | ($9.01M) | - | ($9.21M) | ($15.06M) | ($19.11M) | - | ($8.06M) | ($7.41M) |
| Interest Expense | - | - | - | - | - | $1.13M | $611.0K | - | $419.0K | $349.0K |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($3.27M) | ($8.32M) | ($10.20M) | - | ($10.37M) | ($13.60M) | ($22.12M) | - | ($8.39M) | ($7.31M) |
| EPS - Basic | ($0.09) | ($0.24) | ($0.30) | - | ($0.30) | - | - | - | ($0.33) | - |
| EPS - Diluted | ($0.09) | ($0.24) | ($0.30) | - | ($0.30) | - | - | - | ($0.33) | - |
Balance Sheet
| Line item | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $77.40M | $70.17M | $73.85M | $70.54M | $68.84M | $74.73M | $121.41M | $61.76M | $39.85M | $45.67M |
| Accounts Receivable | $18.72M | $15.28M | $12.94M | $9.81M | $8.30M | $4.22M | $1.14M | $1.20M | $1.05M | $1.21M |
| Inventory | $1.11M | $1.32M | $1.69M | $1.66M | $1.25M | - | - | - | - | - |
| Accounts Payable | $5.04M | $3.60M | $3.01M | $2.71M | $4.92M | $3.16M | $3.96M | $3.38M | $2.00M | $1.78M |
| Current Assets | $100.73M | $97.59M | $97.73M | $104.74M | $107.98M | $111.74M | $126.06M | $65.51M | $71.64M | $74.23M |
| Total Assets | $101.23M | $98.11M | $98.22M | $105.34M | $109.09M | $112.98M | $127.44M | $66.91M | $73.02M | $75.60M |
| Current Liabilities | $42.42M | $31.50M | $20.30M | $18.73M | $22.38M | $17.48M | $19.77M | $16.95M | $16.69M | $21.78M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $72.39M | $67.52M | $61.27M | $59.47M | $57.85M | $52.78M | $54.99M | $31.62M | $32.80M | $27.55M |
| Stockholders' Equity | $28.84M | $30.59M | $36.94M | $45.87M | $51.23M | $60.20M | $72.45M | $35.29M | $40.22M | $48.05M |
| Retained Earnings | ($696.33M) | ($693.07M) | ($684.75M) | ($674.55M) | ($667.29M) | ($656.92M) | ($643.33M) | ($621.21M) | ($609.70M) | ($601.31M) |
Cash Flow
| Line item | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($8.22M) | - | - | - | ($18.33M) | - | - | - |
| Investing Cash Flow | - | - | $0 | - | - | - | - | - | - | - |
| Financing Cash Flow | - | - | $0 | - | - | - | $77.99M | - | - | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 87.0% | 87.9% | 88.4% | - | - | - | - | - | - | - |
| Operating margin | -7.1% | -28.3% | -43.1% | - | -46.1% | -199.4% | -995.6% | - | -223.9% | -988.9% |
| EBITDA margin | - | - | -43.0% | - | - | - | -994.7% | - | - | - |
| Net margin | -10.7% | -32.9% | -48.8% | - | -51.8% | -179.9% | -1152.2% | - | -233.1% | -975.4% |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | 36.4% | 48.7% | 48.6% | - | 37.5% | 91.0% | 301.9% | - | 162.8% | 590.0% |
| SG&A / Revenue | 57.7% | 67.5% | 82.9% | - | 75.7% | 197.5% | 191.3% | - | 161.1% | 498.9% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -3.2% | -8.5% | -10.4% | - | -9.5% | -12.0% | -17.4% | - | -11.5% | -9.7% |
| Return on equity | -11.3% | -27.2% | -27.6% | - | -20.2% | -22.6% | -30.5% | - | -20.9% | -15.2% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.37 | 3.10 | 4.81 | 5.59 | 4.83 | 6.39 | 6.38 | 3.87 | 4.29 | 3.41 |
| Quick ratio | 2.35 | 3.06 | 4.73 | 5.50 | 4.77 | 6.39 | 6.38 | 3.87 | 4.29 | 3.41 |
| Cash ratio | 1.82 | 2.23 | 3.64 | 3.77 | 3.08 | 4.28 | 6.14 | 3.64 | 2.39 | 2.10 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | -13.4x | -31.3x | - | -19.2x | -21.2x |
| Equity multiplier | 3.51 | 3.21 | 2.66 | 2.30 | 2.13 | 1.88 | 1.76 | 1.90 | 1.82 | 1.57 |
| Liabilities / Assets | 0.72 | 0.69 | 0.62 | 0.56 | 0.53 | 0.47 | 0.43 | 0.47 | 0.45 | 0.36 |
| Efficiency | ||||||||||
| Asset turnover | 0.30 | 0.26 | 0.21 | - | 0.18 | 0.07 | 0.02 | - | 0.05 | 0.01 |
| Inventory turnover | 3.58 | 2.32 | 1.44 | - | - | - | - | - | - | - |
| Days sales outstanding | 224d | 220d | 226d | - | 152d | 204d | 217d | - | 107d | 589d |
| Days inventory outstanding | 102d | 157d | 254d | - | - | - | - | - | - | - |
| Days payable outstanding | 464d | 429d | 452d | - | - | - | - | - | - | - |
| Cash conversion cycle | -138d | -52d | 28d | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 52.2% | 234.9% | 989.6% | - | 455.6% | 908.8% | 144.9% | - | -86.0% | 6.5% |
| Revenue CAGR (3y) | 5.8% | 230.2% | 135.0% | - | 100.9% | 159.4% | 23.2% | - | -7.9% | 28.7% |
| Revenue CAGR (5y) | 45.8% | 135.3% | 52.6% | - | 82.3% | 108.2% | 9.8% | - | -25.0% | 41.1% |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 76.5% | 52.5% | 52.9% | - | -14.3% | -103.4% | -78.4% | - | - | -51.3% |
| Net income growth (YoY) | 68.5% | 38.8% | 53.9% | - | -23.5% | -86.1% | -164.0% | - | - | -133.0% |
| EPS growth (YoY) | 70.0% | - | - | - | 9.1% | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -43.7% | -49.2% | -49.0% | 30.0% | 27.4% | 25.3% | 933.8% | 137.7% | 114.4% | 2842.6% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$83.14M totalProduct Gross$45.67M · 54.9%
Product$38.87M · 46.8%
Royalty$3.42M · 4.1%
Collaboration And Licensing$1.97M · 2.4%
Product Sales Discounts And Allowances($6.79M) · -8.2%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing AVEO PHARMACEUTICALS against the 5 most active filers in the same SIC group.